Document:

EX-10.1H

 Exhibit 10.1(h) 

PLEDGE SUPPLEMENT 
 This
Pledge Supplement is dated as of October 3, 2016 and is provided in accordance with the terms of the Pledge Agreement referenced below. The undersigned directs that this Pledge Supplement be attached to the Pledge Agreement, dated as of
October 3, 2016 by and among GREEN PLAINS I LLC, a Delaware limited liability company, GREEN PLAINS II LLC, a Delaware limited liability company, and each other person who joined thereto as a Pledgor, and Maranon Capital, L.P., in its capacity as
Agent (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Pledge Agreement”; capitalized terms used and not defined herein having the meanings assigned thereto in the Pledge
Agreement) and that the equity interests listed below shall be deemed to be part of the Pledged Collateral. 
 The undersigned hereby
certifies that the representations and warranties in Section 4 of the Pledge Agreement are true and correct, as to the shares and other property pledged pursuant to this Pledge Supplement. The undersigned further agrees that this Pledge
Supplement may be attached to the Pledge Agreement and that the Pledged Securities listed on this Pledge Supplement are a part of the Pledged Securities referred to in the Pledge Agreement and shall secure all Obligations referred to in the Pledge
Agreement. 
  

													
	 Issuer
	  	 Class
or
Other
Description of
Pledged
Securities
	  	Certificate
Number (if
applicable)	  	Number of
Pledged
Securities	  	Total
Outstanding
Securities	  	Percentage of
Total
Outstanding
Securities
Pledged	 
	 SCI Ingredients Holdings, Inc.
	  	Common Stock	  	C-2	  	100	  	100	  	 	100	% 

 - REMAINDER OF PAGE INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS - 

 
			
	GREEN PLAINS II LLC
		
	 By
	 	 /s/ Todd Becker

	Name:	 	 Todd Becker

	Title:	 	 President and Chief Executive OfficerEX-10.1I

 Exhibit 10.1(i) 

JOINDER TO PLEDGE AGREEMENT 

This JOINDER TO PLEDGE AGREEMENT (this “Agreement”) dated as of this 3rd day of
October, 2016 is made by the undersigned (individually, the “New Pledgor” and collectively, the “New Pledgors”), to and in favor of Maranon Capital, L.P., as Agent. 

WITNESSETH THAT: 

WHEREAS, Green Plains I LLC, a Delaware limited liability company (“Holdings”) and Green Plains II LLC, a Delaware limited
liability company (“GP II”; GP II together with Holdings and each other person who joined in execution thereof as “Pledgors” and individually as a “Pledgor”), has entered into that certain Pledge
Agreement dated as of October 3, 2016 (such Pledge Agreement, as the same may from time to time be amended, restated, amended and restated, supplemented or otherwise modified, including without limitation, pursuant to joinders thereto which add
additional parties as “Pledgors” thereunder, being hereinafter referred to as the “Pledge Agreement”; capitalized terms used in this Agreement and not defined in this Agreement shall have the meanings ascribed to such
terms in the Pledge Agreement) with Agent; and 
 WHEREAS, it is a condition to the continuing extension of Loans and other financial
accommodations by the Lenders under the Credit Agreement that the New Pledgors be joined as party to the Pledge Agreement; and 
 WHEREAS,
it is to the direct economic benefit of New Pledgors to execute and deliver this Agreement and be joined as party to the Pledge Agreement; 

NOW, THEREFORE, FOR VALUE RECEIVED, and in consideration of advances made or to be made, or financial accommodations given or to be given, to
the New Pledgors by Lenders from time to time, each New Pledgor hereby agrees as follows: 
 1. Each New Pledgor acknowledges and agrees
that it is a “Pledgor” under the Pledge Agreement effective upon the date of such New Pledgor’s execution and delivery to Agent of this Agreement. Effective upon such delivery, all references in the Pledge Agreement and the other
Loan Documents (with respect to the Loan Documents, to the extent the applicable reference relates to the Pledge Agreement) to the term “Pledgor” or “Pledgors” shall be deemed to include each New Pledgor. Without limiting
the generality of the foregoing, each New Pledgor (i) hereby repeats and reaffirms all covenants, agreements, representations and warranties contained in the Pledge Agreement attributable to Pledgors and (ii) agrees to be bound by all of the terms
and provisions of the Pledge Agreement as Pledgor thereunder. 
 2. Each New Pledgor hereby acknowledges and agrees that it is jointly and
severally liable with all other Pledgors under the Pledge Agreement to the same extent and with the same force and effect as if such New Pledgor had originally been signatory to the Pledge Agreement as “Pledgor” thereunder and had
originally executed the same in such capacity. Except as specifically modified hereby, all of the terms and conditions of the Pledge Agreement shall remain unchanged and in full force and effect. 

3. Each New Pledgor agrees to execute and deliver such further instruments and documents and do such further acts and things as required by
the terms of the Loan Documents in accordance with the terms thereof. 

  
 1 

 4. Each New Pledgor hereby consents to and affirms the grant of liens and security interests to
and in favor of Agent pursuant to Section 2 of the Pledge Agreement and, in connection therewith, by its signature hereto, hereby pledges, assigns, hypothecates, collaterally transfers, delivers and grants to Agent, as Pledgee under the Pledge
Agreement and for the benefit of the Secured Parties, subject to all terms and provisions of the Pledge Agreement, a lien on and security interest in and to all of such New Pledgor’s right, title and interest in and to all Pledged Collateral of
such New Pledgor, including, without limitation, all Pledged Collateral described on Annex A attached hereto. The parties hereto hereby agree that Exhibit A to the Pledge Agreement shall be deemed supplemented to include the information set
forth on Annex A attached hereto. 
 5. No reference to this Agreement need be made in the Pledge Agreement or other document or instrument
(including any other Loan Document) making reference to the same, any reference to the Pledge Agreement in any of such to be deemed a reference to the Pledge Agreement as modified hereby. Either an original or a copy of this Agreement may be
attached to the Pledge Agreement as an allonge thereto to evidence each New Pledgor’s acknowledgment of the full force and effect of this Agreement to bind such New Pledgor to the terms of the Pledge Agreement as “Pledgor” thereunder;
provided failure to so affix this Agreement as an allonge to the Pledge Agreement shall in no way limit such New Pledgor’s agreement hereunder to be bound by all of the terms and provisions of the Pledge Agreement as “Pledgor”
thereunder. 
 6. THE LAWS OF THE STATE OF ILLINOIS SHALL GOVERN ALL MATTERS ARISING OUT OF, IN CONNECTION WITH OR RELATING TO THIS
AGREEMENT, INCLUDING ITS VALIDITY, INTERPRETATION, CONSTRUCTION, PERFORMANCE AND ENFORCEMENT (INCLUDING ANY CLAIMS SOUNDING IN CONTRACT OR TORT LAW ARISING OUT OF THE SUBJECT MATTER HEREOF AND ANY DETERMINATIONS WITH RESPECT TO POST-JUDGMENT
INTEREST). 
 7. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if
the signatures thereto and hereto were upon the same instrument. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart
hereof. 
 - REMAINDER OF PAGE INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS- 

  
 2 

 Witness the due execution hereof by the respective duly authorized officers of the undersigned as
of the date first written above. 
  

			
	NEW PLEDGORS:
	
	SCI INGREDIENTS HOLDINGS, INC.
		
	By:	 	 /s/ Todd Becker

	Name:	 	Todd Becker
	Title:	 	Executive Chairman
	
	FVC INTERMEDIATE HOLDINGS, INC.
		
	By:	 	 /s/ Todd Becker

	Name:	 	Todd Becker
	Title:	 	Executive Chairman
	
	FLEISCHMANN’S VINEGAR COMPANY, INC.
		
	By:	 	 /s/ Todd Becker

	Name:	 	Todd Becker
	Title:	 	Executive Chairman
	
	FVC HOUSTON, INC.
		
	By:	 	 /s/ Todd Becker

	Name:	 	Todd Becker
	Title:	 	Executive Chairman

 Joinder to Pledge Agreement (FVC) 

			
	Acknowledged and Agreed to:
	
	MARANON CAPITAL, L.P.,
	as Agent
		
	By:	 	 /s/ Gregory M. Long

	Name:	 	Gregory M. Long
	Title:	 	Managing Director

 Joinder to Pledge Agreement (FVC) 

 ANNEX A 

Identification of Pledged Securities 
  

															
	 Issuer
	  	 Pledgor
	  	Class or
Other
Description
of Pledged
Securities	  	Certificate
Number
(if
applicable)	  	Number
of
Pledged
Securities	  	Total
Outstanding
Securities	  	Percentage
of Total
Outstanding
Securities
Pledged	 
	 FVC Intermediate Holdings, Inc.
	  	SCI Ingredients Holdings, Inc.	  	Common
Stock	  	C-B-13	  	100	  	100	  	 	100	% 
	 Fleischmann’s Vinegar Company, Inc.
	  	FVC Intermediate Holdings, Inc.	  	Common
Stock	  	C-A-2	  	100	  	100	  	 	100	% 
	 FVC Houston, Inc.
	  	Fleischmann’s Vinegar Company, Inc.	  	Common
Stock	  	C-1	  	100	  	100	  	 	100	%Exhibit 10.1

 

AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT

 

Amendment (this “Amendment”)
dated as of September 27, 2016 to the Executive Employment Agreement (the “Agreement”) dated October 13, 2015, by and
between Checkpoint Therapeutics, Inc. (the “Company” or “Checkpoint”) and James F. Oliviero III (“Oliviero”).
All capitalized terms not otherwise defined herein shall have the meanings given to them in the Agreement.

 

WHEREAS, on October 13, 2015, Oliviero received
a grant of 1,000,000 restricted shares of Checkpoint common stock, $0.0001 par value, and pursuant to the Agreement 333,333 of
such shares (the “Shares”) are set to vest over time in four equal annual installments beginning on the Effective Date;

 

WHEREAS, on September 27, 2016, Oliviero
and the Company agreed to amend the vesting schedule in the Agreement;

 

WHEREAS, the Company believes that it is
in its best interest to amend the vesting schedule in the Agreement; and

 

WHEREAS, the Company and Oliviero have agreed
to amend the Agreement.

 

NOW THEREFORE, in consideration of the foregoing
and of the mutual covenants hereinafter set forth, the parties agree as follows:

 

1.            Amendments.

 

Section 3.4.3 of the Agreement
with regard to the Shares shall be amended by deleting the phrase “One-third of the Shares will vest over time in four equal
annual installments beginning on the Effective Date. One-third of the Shares will vest in three equal parts based on the Company’s
achievement of fully-diluted Market Capitalization of $250,000,000, $500,000,000, and $750,000,000 respectively. For purposes of
this Agreement, “Market Capitalization” shall be determined by multiplying the total shares of the Company’s
common stock that are outstanding (including common stock issuable upon conversion, exchange or exercise of any derivative security,
including without limitation, options, warrants, convertible equity or debt or restricted equity) by the last reported closing
price of the Company’s common stock on a nationally recognized exchange or in the over-the-counter market. The final third
will vest in two equal installments as follows: (i) one installment will vest upon the earlier of (A) the Company’s first
Corporate Development Transaction (as defined below) or (B) the first FDA approval of a Company product or medical device, and
(ii) the second installment will vest upon the earlier of (A) the Company’s second Corporate Development Transaction (as
defined below) or (B) a second FDA approval of a Company product or medical device” and inserting the following:

 

     

     

    

 

The Shares will vest over time
pursuant to the following schedule:

 

	Vesting Date	 	Number of Shares Vested
	 	 	 
	October 13, 2017	 	166,667
	October 13, 2018	 	83,333
	October 13, 2019	 	83,333
	The first date that the Company achieves a fully-diluted Market Capitalization (as defined in the Employment Agreement) of $250,000,000	 	111,111
	The first date that the Company achieves a fully-diluted Market Capitalization (as defined in the Employment Agreement) of $500,000,000	 	111,111
	The first date that the Company achieves a fully-diluted Market Capitalization (as defined in the Employment Agreement) of $750,000,000	 	111,111
	The earlier to occur of: (A) the Company’s first Corporate Development Transaction (as defined in the Employment Agreement) or (B) the first FDA approval of a Company product or medical device	 	166,667
	The earlier to occur of: (A) the Company’s second Corporate Development Transaction (as defined in the Employment Agreement) or (B) a second FDA approval of a Company product or medical device	 	166,667

 

For purposes of this Agreement,
“Market Capitalization” shall be determined by multiplying the total shares of the Company’s common
stock that are outstanding (including common stock issuable upon conversion, exchange or exercise of any derivative security, including
without limitation, options, warrants, convertible equity or debt or restricted equity) by the last reported closing price of the
Company’s common stock on a nationally recognized exchange or in the over-the-counter market.

 

2.            Effect
on the Agreement.

 

(a)          Upon the effectiveness
of this Amendment, each reference in the Agreement to “this Agreement” “hereunder”, “hereof”,
“herein” or words of like import shall mean and be a reference to the Agreement as amended hereby.

 

(b)          Except
as expressly amended, the Agreement and all other documents and agreements executed and/or delivered in connection therewith, shall
remain in full force and effect.

 

3.            Governing
Law.

 

This Amendment shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and assigns and shall be governed by and construed
in accordance with the laws of the State of New York without regard to its conflict of laws principles. 

 

    	 	- 2 -	 

     

    

 

4.            Counterparts.

 

This Amendment may be executed
by the parties hereto in one or more counterparts, each of which shall be deemed an original and all of which when taken together
shall constitute one and the same agreement.

 

IN WITNESS WHEREOF, Checkpoint Therapeutics,
Inc. and James F. Oliviero III have executed this Amendment to the Executive Employment Agreement as of the date first written
above.

 

	 	CHECKPOINT THERAPEUTICS, INC.
	 	 
	 	By:	/s/ Michael S. Weiss
	 	 	Michael S. Weiss
	 	 	Executive Chairman
	 	 
	 	/s/ James F. Oliviero III
	 	James F. Oliviero III

 

    	 	- 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]